# 2026-07370: RSV Vaccine for Rare Kid Illnesses Gets Speedy FDA Nod

2026-07370, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-16, effective 2025-06-12; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-07370
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-07370
- Title: Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 20471
- Published: 2026-04-16
- Effective: 2025-06-12
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

RSV Vaccine for Rare Kid Illnesses Gets Speedy FDA Nod

## Summary

The FDA just gave the green light to MRESVIA, a vaccine for a rare but serious lung virus in kids, using a special priority review voucher. This means faster approval for important medicines that help rare pediatric diseases, speeding up access for families who need them. The approval was finalized on June 12, 2025, marking a big win for rare disease treatments and encouraging more innovation.

## Abstract

The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that MRESVIA (Respiratory Syncytial Virus Vaccine), BLA supplement approved June 12, 2025, meets the criteria for redeeming a priority review voucher.

## Effects PRIA read

- FDA Approves MRESVIA Using Rare Pediatric Voucher: benefit, high. If you are a parent of a child affected by the targeted illness, the FDA approved MRESVIA (Respiratory Syncytial Virus Vaccine) via a Biologics License Application supplement on June 12, 2025. The FDA determined this approval redeemed a Rare Pediatric Disease Priority Review Voucher and published n…

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-07370 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/16/2026-07370/notice-of-approval-of-product-under-voucher-rare-pediatric-disease-priority-review-voucher-mresvia)
- [2026-07370 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-16/pdf/2026-07370.pdf)

## Related
- [Previous: 2026-07369, Notice of Approval of Product Under Priority Review Voucher; Material Threat Me…](https://policyrisk.com/federal-register/2026-07369)
- [Next: 2026-07371, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Re…](https://policyrisk.com/federal-register/2026-07371)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-07370 (as of 2026-06-08).